Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

rong allergy season. Despite major disasters occurred at the beginning of March, our Kawagoe factory and our distribution centers were unaffected.

First-quarter net sales in the U.S. reached euro 2,165 million, down 3.3%. This decrease reflected the impact of generics of Lovenox®, Ambien®CR, and Taxotere® which was partially offset by the successful launch of Allegra® OTC (euro 80 million) and strong growth of Lantus®, Multaq®, Jevtana® and Merial.

Western Europe recorded net sales in the first quarter of euro 2,251 million, a decrease of 13.5% and were impacted by generic competition to Plavix® (-46.6%) and Taxotere® (-61.3%) and austerity measures.

R&D update Since the last R&D update on February 9, several compounds/Vaccines entered Phase I, Phase II or Phase III and additional partnerships with companies and academia were signed. At the end of April, sanofi-aventis portfolio comprised 64 new molecular entities and vaccines in clinical development of which 17 are in Phase III or have been submitted to the health authorities for approval.

With the completion of the acquisition of Genzyme in April, sanofi-aventis' R&D significantly expanded its presence in biotechnology and in the Boston area, a region recognized worldwide for excellence in the sciences. Genzyme has enriched the Group's pipeline with 10 new molecular entities currently in clinical development. Genzyme R&D has three near term opportunities: alemtuzumab for multiple sclerosis, mipomersen for patients with homozygous familial hypercholesterolemia (hoFH) or severe heterozygous familial hypercholesterolemia (heFH) and eliglustat an oral therapy for type 1 Gaucher Disease.

The entire Genzyme pipeline will be subject to a thorough portfolio analysis in the coming months to identify portfolio priorities.

Throughout 2011, fu
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... 2014   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... from its pivotal field study of AT-001 (Grapiprant), ... dogs with osteoarthritis.  In the study, dogs receiving ... were statistically significant compared to placebo (p<0.05) at ...
(Date:12/17/2014)... December 17, 2014 Revenue and earnings ... on research and development In the past 2013/14 ... by two percent to EUR 4.287 billion (last year: EUR ... 14 percent to EUR 360 million. "Overall, 2013/14 was a ... Michael Kaschke , President and CEO of Carl Zeiss AG. ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... 2010 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... to offer its common stock in a registered public offering ... Act of 1933. Stereotaxis also intends to grant the underwriters ... common stock to cover over-allotments, if any. Stereotaxis ...
... 10, 2010 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, ...   Interested parties may access a live webcast ... It is recommended that listeners log on 15 ...
Cached Medicine Technology:Stereotaxis Announces Public Offering of Common Stock 2Stereotaxis Announces Public Offering of Common Stock 3Stereotaxis Announces Public Offering of Common Stock 4Onyx Pharmaceuticals to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:12/20/2014)... 2014 BambooIndustry.com is a ... business has announced its bamboo flooring promotion for ... material from certified suppliers, and offers the best ... In the current promotion, all customers can enjoy ... they say they know BambooIndustry.com from press releases. ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... with the healthcare sector have benefited the Massage ... Given the discretionary characteristics of industry products, the anticipated ... the five-year period has provided consumers with the means ... adults that have received a massage in a given ...
(Date:12/20/2014)... The print component of Healthy Aging is distributed ... 160,000 copies and an estimated readership of 420,000. The ... media strategy and across a network of top news ... of the campaign, click here . , The ... of CTV’s The Social. Lainey Lui, Melissa Grelo, ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New ... a decade. They’ve treated over 40,000 patients while carrying ... alternative to the Paramus area. , For 2015, ... their staff of top-notch board certified physicians: Christine Milosis MD, ... These new doctors will work tirelessly to carry out The ...
(Date:12/20/2014)... CA (PRWEB) December 20, 2014 Atore, ... Innovation company just launched first birthday focused portal on ... “MERRY BIRTHDAY MESSAGE” launched in both US and Japan. ... BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY ... everyone’s birthday around the world. , Features, Choose from ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2
... the first in the country to offer skin transplant ... with the skin disease vitiligo. The surgery, known ... taken from normally pigmented areas of the body and ... restore pigmentation. It is performed under local anesthesia as ...
... one day serve as an alternative to steroid medications and ... on research findings at the Salk Institute for Biological Studies. ... in Salk,s Laboratory of Genetics and Ronald M. Evans, the ... that defends the body against cancer also plays a key ...
... Cypress, CA -- As many as 10 million American ... gastrointestinal and urinary tract difficulties and infertility due to ... the lining of the uterus the endometrium ... uterus. This year,s annual meeting of gynecologic laparoscopic ...
... sun can give rise to skin cancer has increased, so ... can give rise to contact allergy when exposed to the ... skin allergy. Scientists at the University of Gothenburg and Chalmers ... UV filter that does not have undesired effects., , "Unfortunately, ...
... TUESDAY, Oct. 25 (HealthDay News) -- Researchers have identified ... effect on the rate at which men experience an ... 144 experienced U.S. male pilots over the age of ... test three times over two years. The participants included ...
... 25, 2011 Researchers at Tenon Hospital, Paris, France, ... improved after cataract surgery also showed improvement in cognitive ... Brigitte Girard, MD, will discuss her team,s results today ... This is the first study to specifically assess ...
Cached Medicine News:Health News:Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo 2Health News:Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo 3Health News:New anti-inflammatory drugs might help avoid side effects of steroids 2Health News:New anti-inflammatory drugs might help avoid side effects of steroids 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 2Health News:Close-up on endometriosis at 40th AAGL Global Congress 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 4Health News:A substance from bacteria can lead to allergy-free sunscreen 2Health News:Aging Brain's Decline May Hinge on a Gene 2Health News:Mood, cognition and sleep patterns improve in Alzheimer's patients after cataract surgery 2
... The 1081 is an all-in-one drape ... The drape includes a pouch with filter ... finger cot. 64 inches (164cm) TUR ... Elastic aperture, Neoprene finger cot, Fluid collection ...
... Both the Penilab IV and the Penilab V ... studies. Model 1060 is similar to the Model ... nor can one be added later. The Penilab ... including all of the accessories you'll need to get ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... II SP MRI-Compatible Anesthesia System is perfect for ... than one type of anesthetic agent. , ... due to its wider stance, has a larger ... bellows assembly is utilized in both the Integra ...
Medicine Products: